ProgrammableMarketing/10xscience.com (opens in a new tab)
PDF

Views

  • Plan
  • Roadmap
  • Research

On this page

  • The brief
  • Start here
  • Idea portfolio
  • Effort vs impact
  • This week · 7
  • This quarter · 12
  • Big bets · 2
  • Wildcards · 1
  • How we can help
Generated Nov 10, 2026
  1. Programmable
  2. Playbooks
  3. 10x Science
10x Science logo

growth playbook · Nov 10, 2026

10xscience.com (opens in a new tab)

10x Science growth playbook

Diagnosis

10x Science is a five-person YC Winter 2026 company with a $4.8M seed led by Initialized, founders from Carolyn Bertozzi's Stanford lab, and paying work with top-10 pharma.

Its biggest marketing problem is invisible in a browser: every page on 10xscience.com sends only its title in the HTML, so AI assistants, link previews and many research tools see a single sentence, and press rewrites have filled the gap with wrong facts (Charlottesville, W25).

There is also no product page, benchmark, case study, compliance page or buying path behind a demo button. This playbook makes the site readable first, then adds the proof that analytical buyers need (a NISTmAb benchmark, a traceability page, the first customer story) and a clear pilot-to-subscription path, and builds the CRO, academic and AI-design channels.

Growth Score

6/10

Biggest Opportunity

Turn the scientific credibility the press already reports into proof on its own site that buyers can read and verify: a readable site, a public benchmark, a traceability page and a fixed-scope pilot.

Biggest Risk

Established, vendor-neutral tools (PEAKS, Protein Metrics by Dotmatics, Genedata Expressionist) and instrument-vendor software already sit inside validated lab workflows, and pharma will not switch without published accuracy and compliance evidence.

01

Start here

The three moves to make first. Each one is written up in full below.

  1. 1

    Make the site readable without JavaScript: every 10x Science page currently sends only its title

    Fetch the homepage with JavaScript off and list every headline and claim missing from the response.

    High impact First result in 2-4 weeks
  2. 2

    Turn the analytical lab already using the platform into the first case study, with time saved per peptide map

    Ask the lab for permission and one before-and-after number.

    High impact First result in 3 weeks
  3. 3

    Give each blog post its own title, description and share image, so the seed announcement stops sharing as the homepage

    Write a title and description for each of the four posts.

    Medium impact First result in 1 week

02

Your idea portfolio

22 ideas, grouped by when to run them. Open any idea for how to run it: the steps, who to approach, copy you can use, and how to measure it.

  • 9 ideas are marked Unexpected: plays you are unlikely to have tried.

    1 of these are things Programmable can build and run for you.

Every idea placed by the effort it takes against the impact it could have. Quick wins sit top left; select a number to open that idea. The filters below narrow the list by status, timing, category and what Programmable can build.

Effort vs impactEach number is an idea. Select one to open it.
Impact →
Quick wins · 3Big bets · 10Fill-ins · 6Reconsider · 3
Effort →

Showing 22 of 22 ideas

This week 7

Quick wins with a clear first action.

  • 01

    Fetch any page on 10xscience.com without running JavaScript (the homepage, /blog, the seed announcement, /careers, /changelog) and the response is the same single line: "10x Science: AI-Native Software for Scientists". The H1 about next-generation protein characterization, the peptide-mapping claims ("10x faster processing", "Find what current tools miss", "No file conversions") and every blog post appear only after the JavaScript runs. Google renders JavaScript, which is why the lab SEO score is 100, but AI assistant crawlers, link previews, many research tools and press-aggregator bots do not, so they find one sentence. That gap is probably why third-party profiles have filled in wrong facts.

    High impactLow effort First result in 2-4 weeks Founding Engineer

    First action

    Fetch the homepage with JavaScript off and list every headline and claim missing from the response.

    How to measure it

    Pages readable without JavaScript

    Now
    –
    Target
    All 9 public pages
    By
    2 weeks

    Steps

    1. 1

      Confirm the gap

      Fetch each sitemap URL plus /careers and /changelog with JavaScript off and record what is missing.

      Founding Engineer 1 hour

    2. 2

      Choose the render mode

      Static prerender at build for marketing pages; the app stays client-side.

      CTO 1 day

    3. 3

      Prerender the pages

      Homepage, /brand, /blog, the four posts, /careers and /changelog.

      Founding Engineer 3 days

    4. 4

      Write per-page head tags

      Unique title, description, canonical and Open Graph tags for each URL.

      Founding Engineer 1 day

    5. 5

      Add structured data

      Organization and SoftwareApplication JSON-LD with founders, San Francisco, the seed round and press links.

      Founding Engineer 2 hours

    6. 6

      Complete the sitemap

      Add /careers and /changelog, with lastmod dates.

      Founding Engineer 1 hour

    7. 7

      Verify

      No-JavaScript fetch, Search Console URL inspection and a LinkedIn post inspector on every page.

      CTO 1 day

    First result
    2-4 weeks
    Cost
    Engineering time only, about one week
    Owner
    Founding Engineer

    Smallest test

    Prerender the homepage alone and compare the raw HTML before and after.

    Why it works

    Prerender the public marketing pages (static generation at build, or server-side rendering) so each one sends its headline, body copy, its own title and description, and structured data (Organization and SoftwareApplication, with founders, location, funding and the product category) in the first HTML response. Keep animations and the Cal.com scheduler as enhancements that load afterwards. The app at its own subdomain stays as it is. Then check every URL with a no-JavaScript fetch, a link-preview inspector and Search Console.

    Analytical scientists and procurement teams increasingly start vendor research in AI assistants and shared links. If the HTML holds the real claims, those tools quote 10x Science's own words instead of third-party rewrites, and every later idea in this playbook (product page, benchmark, case study) becomes readable too.

    Ready to use

    ChecklistReadable-site checklist

    [ ] H1 and body copy in raw HTML on all 9 public pages
    [ ] Unique <title> and meta description per URL
    [ ] Open Graph title, description and image per URL
    [ ] Canonical tag per URL
    [ ] Organization + SoftwareApplication JSON-LD
    [ ] /careers and /changelog added to the sitemap
    [ ] No-JS fetch, Search Console and LinkedIn inspector all pass

    Risks and how to handle them

    • Prerendered and live pages drift apart visually

      Compare screenshots before and after for each page.

    • Animations break when content is in the HTML

      Treat motion as a layer added after load, not the source of the text.

    Evidence

    • Your websiteRaw HTML check (November 9, 2026, repeated): every public URL tested (/, /blog, /blog/2026/04/seed-announcement, /blog/2026/02/extreme-velocity, /pricing, /careers, /changelog) returns the same single line, the title "10x Science: AI-Native Software for Scientists", with no headings, body text or post titles. Everything visitors read is drawn by JavaScript after load, so a reader that does not run JavaScript sees one sentence for the whole site.Source
    • Your websiteHomepage (rendered scan): H1 "The AI-native platform for next-generation protein characterization."; meta description "Peptide mapping, upgraded for protein therapeutics. 10x faster processing. Find what current tools miss. No file conversions, no friction."; logos for Y Combinator, Stanford, MIT, UC Berkeley, UCSF and UW Madison; no testimonials or case studies; demos booked through an embedded Cal.com scheduler; no free trial or published pricing. The headline changed from "Science" to the current message after December 2025.Source
    • Google PageSpeedHomepage, mobile lab test: performance 37/100, largest paint 4.7s (the H1), total blocking time 2.8s, 5.3 MB downloaded (2.3 MB images, 0.9 MB fonts, 0.9 MB JavaScript), 3,356 page elements; the biggest fixes are unused JavaScript (about 1.8s) and image delivery (about 2.1 MB). Real Chrome visitors (75th percentile) load fast: LCP 1.7s and INP 140 ms are both good and LCP is 13% faster than before, but layout shift is 0.14, above the 0.1 "good" limit. Accessibility, best practices and SEO each score 100 in the lab test, which runs JavaScript.Source
    • News coverageThird-party profiles disagree on basic facts: a seed write-up calls 10x Science "Charlottesville-based" while YC lists San Francisco, and a March 2026 feature calls it YC W25 while YC's directory says Winter 2026. Many results for the company are automated rewrites of the TechCrunch story.Source
  • 02

    In the raw HTML, the seed announcement, the YC launch post and "Extreme Velocity" all carry the homepage title. LinkedIn, Slack, X and email clients build link previews from that HTML, so the posts most likely to be shared by investors, YC peers and scientists preview as a generic homepage card instead of "10x Science raises $4.8M".

    Medium impactLow effort First result in 1 week COO

    First action

    Write a title and description for each of the four posts.

    How to measure it

    Social referral sessions to /blog

    Now
    –
    Target
    2x
    By
    60 days

    Steps

    1. 1

      Write the copy

      Title and description for each of the four posts.

      COO 2 hours

    2. 2

      Make share images

      One 1200x630 image per post.

      COO half a day

    3. 3

      Add the tags

      Open Graph, Twitter card and article JSON-LD in the prerendered HTML.

      Founding Engineer 2 hours

    4. 4

      Inspect previews

      LinkedIn post inspector and a Slack test for each URL.

      Founding Engineer 1 hour

    5. 5

      Re-share

      Founders re-post the seed announcement with the new card.

      CEO 1 hour

    6. 6

      Template it

      Make the tags required fields for every new post.

      Founding Engineer 2 hours

    First result
    1 week
    Cost
    $0
    Owner
    COO

    Smallest test

    Fix the seed announcement's preview and share it once.

    Why it works

    Give each post a specific title, a one-sentence description and a share image (for example the round, the investors' logos, or a spectrum graphic), plus article structured data with date and author. Re-share the seed post once the preview is fixed.

    A specific preview is what earns the click in a feed; the seed news is the strongest credibility signal the company has and should travel as such.

    Risks and how to handle them

    • Platforms cache the old preview

      Force a re-scrape in each platform's inspector.

    Builds on

    Evidence

    • Your websiteRaw HTML check (November 9, 2026, repeated): every public URL tested (/, /blog, /blog/2026/04/seed-announcement, /blog/2026/02/extreme-velocity, /pricing, /careers, /changelog) returns the same single line, the title "10x Science: AI-Native Software for Scientists", with no headings, body text or post titles. Everything visitors read is drawn by JavaScript after load, so a reader that does not run JavaScript sees one sentence for the whole site.Source
    • Your websiteSitemap (7 URLs): the homepage, /brand, /blog and four posts ("YC Announcement", January 2026; "YC Launch" and "Extreme Velocity", February 2026; "Seed Announcement", April 2026). There are no product, peptide-mapping, use-case, docs, customer, careers or changelog pages in it, although the site links to /careers and /changelog.Source
  • 03

    With nothing readable on its own site, 10x Science is described by others: one seed write-up says "Charlottesville-based", a feature says YC W25, and many results are automated rewrites of TechCrunch. Pharma diligence teams, recruiters and AI assistants pick up whichever version they find first.

    Medium impactLow effort First result in 2 weeks COO

    First action

    List every profile with a wrong location or batch.

    How to measure it

    Correct profiles among the top 20 search results

    Now
    –
    Target
    18 of 20
    By
    60 days

    Steps

    1. 1

      Audit profiles

      Top 20 search results for the company name; note each error.

      COO 2 hours

    2. 2

      Write the facts

      Founding, location, batch, round, investors, founders, product in one paragraph.

      COO 2 hours

    3. 3

      Publish the page

      Prerendered /about with press links and the /brand kit.

      Founding Engineer half a day

    4. 4

      Add structured data

      Organization JSON-LD with founders, location and sameAs links.

      Founding Engineer 1 hour

    5. 5

      Request corrections

      Email each site with an error, linking the page.

      COO 1 day

    6. 6

      Claim profiles

      Update the directory profiles the company can edit.

      COO half a day

    First result
    2 weeks
    Cost
    $0
    Owner
    COO

    Smallest test

    Publish the page and request one correction.

    Why it works

    Add a prerendered /about or /press page with the canonical facts: founded December 2025, San Francisco, YC Winter 2026, $4.8M seed led by Initialized with Y Combinator, Civilization Ventures and Founder Factor, the three founders and their Bertozzi-lab background, a one-paragraph product description, press links and the existing /brand kit. Then ask the sites with errors to correct them, and update the Crunchbase-style profiles the company controls.

    A single authoritative page gives journalists, data providers and AI assistants a source to cite, and corrections are easy to request when the facts are published.

    Risks and how to handle them

    • Automated sites never update

      Focus on the sources that rank and that AI assistants cite.

    Evidence

    • News coverageThird-party profiles disagree on basic facts: a seed write-up calls 10x Science "Charlottesville-based" while YC lists San Francisco, and a March 2026 feature calls it YC W25 while YC's directory says Winter 2026. Many results for the company are automated rewrites of the TechCrunch story.Source
    • Y CombinatorYC directory: batch Winter 2026, team of 5, San Francisco, founded 2025, tagged SaaS, B2B, Biotech and AI. The launch post, "10x Science: Unlocking the future of drug development", argues the bottleneck is characterization, not candidate design, and says the team is onboarding customers.Source
    • Your websiteSitemap (7 URLs): the homepage, /brand, /blog and four posts ("YC Announcement", January 2026; "YC Launch" and "Extreme Velocity", February 2026; "Seed Announcement", April 2026). There are no product, peptide-mapping, use-case, docs, customer, careers or changelog pages in it, although the site links to /careers and /changelog.Source
  • 04

    TechCrunch named Rilas Technologies, a lab that runs chemical analyses for clients, as a user that said the platform speeds up its work. The homepage has university and YC logos but no testimonials or case studies, so the only public customer proof lives in a news article.

    High impactLow effort First result in 3 weeks CEO

    First action

    Ask the lab for permission and one before-and-after number.

    How to measure it

    Homepage demo bookings

    Now
    –
    Target
    +25%
    By
    60 days

    Steps

    1. 1

      Ask permission

      Email the lab for approval and a 30-minute interview.

      CEO 1 day

    2. 2

      Measure

      Hours per peptide map before and after, on the same sample type.

      CTO 1 week

    3. 3

      Write it

      Problem, workflow, result, quote, in one page.

      COO 2 days

    4. 4

      Customer review

      The lab approves every number and quote.

      CEO 3 days

    5. 5

      Publish

      Prerendered case study page plus a homepage proof line.

      Founding Engineer 1 day

    6. 6

      Use it in sales

      Link it in every demo follow-up.

      CEO ongoing

    First result
    3 weeks
    Cost
    Staff time only
    Owner
    CEO

    Smallest test

    Add one approved quote under the homepage logos.

    Why it works

    With the lab's approval, publish a short case study: the sample type, the old workflow and its hours per peptide map, the time with 10x Science, what the software found or flagged, and a quote. Put a one-line version on the homepage next to the logos and in the demo follow-up email. Ask the top-10 pharma users for anonymised numbers for a second story.

    Analytical buyers trust a peer lab's measured time savings more than a vendor's "10x faster", and a service lab is a credible, neutral voice.

    Risks and how to handle them

    • The customer declines to be named

      Publish an anonymised story ("a US analytical services lab") with the same numbers.

    Evidence

    • News coverageTechCrunch (April 22, 2026): founded December 2025; $4.8M seed led by Initialized Capital with Y Combinator, Civilization Ventures and Founder Factor; the founders worked in Nobel laureate Carolyn Bertozzi's Stanford lab; the platform pairs deterministic algorithms grounded in chemistry and biology with AI agents that interpret mass spectrometry data, and makes analyses traceable for regulatory compliance; it works with multiple major pharmaceutical companies and academic researchers; Rilas Technologies, which runs chemical analyses for clients, had used it for several weeks and said it speeds up its work; Initialized's Zoe Perret: "This is a SaaS platform that pharma has to pay for, every single month"; the money goes to more engineers, model refinement and new customers, and longer term to combining protein data with other cell data.Source
    • Your websiteHomepage (rendered scan): H1 "The AI-native platform for next-generation protein characterization."; meta description "Peptide mapping, upgraded for protein therapeutics. 10x faster processing. Find what current tools miss. No file conversions, no friction."; logos for Y Combinator, Stanford, MIT, UC Berkeley, UCSF and UW Madison; no testimonials or case studies; demos booked through an embedded Cal.com scheduler; no free trial or published pricing. The headline changed from "Science" to the current message after December 2025.Source
  • 05

    Real Chrome visitors already get a fast homepage (LCP 1.7s, INP 140 ms, both good), but layout shift is 0.14, above Google's 0.1 "good" limit, so the page fails Core Web Vitals on that one measure. In the phone lab test the page weighs 5.3 MB, including 2.3 MB of images and 0.9 MB of fonts, and blocks the main thread for 2.8s.

    Medium impactLow effort First result in 1 month Founding Engineer

    First action

    Record a load with layout-shift regions shown and list the elements that move.

    How to measure it

    CrUX CLS p75

    Now
    –
    Target
    Below 0.1
    By
    45 days

    Steps

    1. 1

      Find the shifts

      Performance panel with layout-shift regions on a phone profile.

      Founding Engineer 2 hours

    2. 2

      Reserve space

      Width and height on logos and hero images.

      Founding Engineer 2 hours

    3. 3

      Tame fonts

      Subset, font-display swap, size-adjusted fallback.

      Founding Engineer half a day

    4. 4

      Shrink images

      Modern formats at display size.

      Founding Engineer half a day

    5. 5

      Split JavaScript

      Load animation code after the first paint.

      Founding Engineer 1 day

    6. 6

      Watch field data

      Check CrUX CLS after 28 days.

      CTO monthly

    First result
    1 month
    Cost
    Engineering time only
    Owner
    Founding Engineer

    Smallest test

    Add image dimensions and font-display today and rerun the lab test.

    Why it works

    Find what moves during load (likely late-loading fonts and logo or hero images without reserved space) and fix it with width and height attributes, font-display and size-adjusted fallback fonts. Then compress and resize the images (about 2.1 MB to save), subset the fonts and split out unused JavaScript (about 1.8s).

    Scientists often open a vendor site on a phone between experiments or from a conference; a stable, light page keeps them reading, and passing all three vitals helps search ranking.

    Risks and how to handle them

    • Design changes from font fallback

      Tune fallback metrics to match the brand font.

    Evidence

    • Google PageSpeedHomepage, mobile lab test: performance 37/100, largest paint 4.7s (the H1), total blocking time 2.8s, 5.3 MB downloaded (2.3 MB images, 0.9 MB fonts, 0.9 MB JavaScript), 3,356 page elements; the biggest fixes are unused JavaScript (about 1.8s) and image delivery (about 2.1 MB). Real Chrome visitors (75th percentile) load fast: LCP 1.7s and INP 140 ms are both good and LCP is 13% faster than before, but layout shift is 0.14, above the 0.1 "good" limit. Accessibility, best practices and SEO each score 100 in the lab test, which runs JavaScript.Source
  • 06

    Hiring engineers is the first stated use of the seed money, and YC's job board lists an open Founding Engineer role ($150K-$240K, 0.5-2% equity, San Francisco or Menlo Park). The company's own careers page shows only a Customer Success Manager marked "Coming Soon", and in raw HTML it shows nothing at all, so job search engines and candidates who start on 10xscience.com find no opening.

    Medium impactLow effort First result in 2 weeks CTO

    First action

    Copy the YC role into /careers with a fuller description.

    How to measure it

    Applicants from 10xscience.com

    Now
    –
    Target
    20 a month
    By
    60 days

    Steps

    1. 1

      Write the role

      The problems, stack, team and compensation.

      CTO 2 hours

    2. 2

      Publish it

      Prerendered /careers/founding-engineer.

      Founding Engineer 2 hours

    3. 3

      Add JobPosting markup

      Salary range, location and dates.

      Founding Engineer 1 hour

    4. 4

      Link from everywhere

      Footer, YC profile and founders' social bios.

      CEO 1 hour

    5. 5

      Upcoming roles

      Customer Success Manager with a register-interest form.

      COO 1 hour

    6. 6

      Track sources

      Ask every applicant where they found the role.

      CTO ongoing

    First result
    2 weeks
    Cost
    $0
    Owner
    CTO

    Smallest test

    Publish the role page and check it in Google's rich results test.

    Why it works

    Publish the Founding Engineer role on /careers with the real work (mass spec data pipelines, deterministic chemistry algorithms, agent tooling, traceability), the team, compensation and how to apply, plus JobPosting structured data so it appears in Google's job results. Keep the Customer Success Manager listed as upcoming with a 'register interest' link.

    Engineers who search for the company after reading TechCrunch should land on a role, and JobPosting markup gives free distribution in job search.

    Risks and how to handle them

    • Role closes and the page goes stale

      Set validThrough dates and review monthly.

    Builds on

    Evidence

    • HiringFounding Engineer (Y Combinator job board, open now): San Francisco or Menlo Park, $150K-$240K plus 0.50%-2.00% equity, 3+ years' experience; the post says the company is working with multiple top-10 pharma companies and has three scientist-founders from Stanford, MIT and UC Berkeley. The company's own careers page lists only "Customer Success Manager", marked "Coming Soon".Source
    • Your websiteRaw HTML check (November 9, 2026, repeated): every public URL tested (/, /blog, /blog/2026/04/seed-announcement, /blog/2026/02/extreme-velocity, /pricing, /careers, /changelog) returns the same single line, the title "10x Science: AI-Native Software for Scientists", with no headings, body text or post titles. Everything visitors read is drawn by JavaScript after load, so a reader that does not run JavaScript sees one sentence for the whole site.Source
    • News coverageTechCrunch (April 22, 2026): founded December 2025; $4.8M seed led by Initialized Capital with Y Combinator, Civilization Ventures and Founder Factor; the founders worked in Nobel laureate Carolyn Bertozzi's Stanford lab; the platform pairs deterministic algorithms grounded in chemistry and biology with AI agents that interpret mass spectrometry data, and makes analyses traceable for regulatory compliance; it works with multiple major pharmaceutical companies and academic researchers; Rilas Technologies, which runs chemical analyses for clients, had used it for several weeks and said it speeds up its work; Initialized's Zoe Perret: "This is a SaaS platform that pharma has to pay for, every single month"; the money goes to more engineers, model refinement and new customers, and longer term to combining protein data with other cell data.Source
  • 07

    The site links to a /changelog and the blog already has a post called "Extreme Velocity", but the changelog is not in the sitemap and, like every page, sends no readable text in its HTML. For a five-person vendor selling to pharma, a visible release history is evidence that the product is maintained and improving.

    Medium impactLow effort First result in 2 weeks CTO

    First action

    Count the releases since the seed and write the last month's entries in plain language.

    How to measure it

    Monthly changelog sessions

    Now
    –
    Target
    300
    By
    90 days

    Steps

    1. 1

      Gather releases

      Everything shipped since the seed round.

      CTO half a day

    2. 2

      Write for scientists

      What changed for the user, not the code.

      CTO half a day

    3. 3

      Prerender and list

      Static page, sitemap entry and RSS feed.

      Founding Engineer half a day

    4. 4

      Surface it

      Latest three entries on the homepage.

      Founding Engineer 2 hours

    5. 5

      Use in sales

      Monthly 'what's new' note to open deals.

      CEO monthly

    6. 6

      Roll up

      A monthly LinkedIn post from the CTO.

      CTO monthly

    First result
    2 weeks
    Cost
    $0
    Owner
    CTO

    Smallest test

    Publish the last month's entries and send them to open deals.

    Why it works

    Prerender the changelog with dated entries grouped by theme (new modifications detected, speed, file formats supported, traceability features), add it to the sitemap and an RSS feed, and link the latest three entries from the homepage and the demo follow-up email. Publish a monthly roll-up to LinkedIn.

    Procurement and IT reviewers check vendor viability; a steady release cadence answers that before the question is asked, and each entry is a reason to re-contact a prospect.

    Risks and how to handle them

    • Revealing roadmap to competitors

      Describe outcomes, not methods.

    Builds on

    Evidence

    • Your websiteSitemap (7 URLs): the homepage, /brand, /blog and four posts ("YC Announcement", January 2026; "YC Launch" and "Extreme Velocity", February 2026; "Seed Announcement", April 2026). There are no product, peptide-mapping, use-case, docs, customer, careers or changelog pages in it, although the site links to /careers and /changelog.Source
    • Your websiteRaw HTML check (November 9, 2026, repeated): every public URL tested (/, /blog, /blog/2026/04/seed-announcement, /blog/2026/02/extreme-velocity, /pricing, /careers, /changelog) returns the same single line, the title "10x Science: AI-Native Software for Scientists", with no headings, body text or post titles. Everything visitors read is drawn by JavaScript after load, so a reader that does not run JavaScript sees one sentence for the whole site.Source
    • Y CombinatorYC directory: batch Winter 2026, team of 5, San Francisco, founded 2025, tagged SaaS, B2B, Biotech and AI. The launch post, "10x Science: Unlocking the future of drug development", argues the bottleneck is characterization, not candidate design, and says the team is onboarding customers.Source

This quarter 12

The core plays for the next three months.

  • 08

    Peptide mapping is the product's first use case and the meta description leads with it, yet the site has no product or peptide-mapping page: the sitemap is a homepage, a brand page and a blog. Rivals each have product pages: PEAKS for AB and Studio, Protein Metrics for Byos and Byonic, Genedata for Expressionist's peptide mapping and MAM.

    High impactMedium effort First result in 1-2 months CEO

    First action

    Write down the five questions scientists ask in the first ten minutes of a demo.

    How to measure it

    Peptide-mapping page demo rate

    Now
    –
    Target
    4% of visits
    By
    90 days

    Steps

    1. 1

      Collect demo questions

      From the last ten demo calls.

      CEO 1 day

    2. 2

      Draft the page

      Inputs, outputs, traceability, speed, sample report.

      CEO 3 days

    3. 3

      Technical review

      Check every claim against the current release.

      CTO 1 day

    4. 4

      Make a sample report

      From a public reference dataset, not customer data.

      Founding Engineer 2 days

    5. 5

      Publish

      Prerendered, with schema and internal links from the homepage.

      Founding Engineer 1 day

    6. 6

      Measure

      Search impressions and demo rate monthly.

      COO monthly

    First result
    1-2 months
    Cost
    Staff time only
    Owner
    CEO

    Smallest test

    Publish the sample report as a downloadable PDF linked from the homepage.

    Why it works

    Build one prerendered page for the analytical scientist: which instrument raw files it reads without conversion, what it reports (sequence coverage, modifications such as oxidation and deamidation, glycopeptides, confidence and evidence for every call), how the traceable audit trail works, typical run times, and a sample report download. End with a demo booking and a 'send a dataset' option.

    Scientists search for the method, not the company. A page that answers "which files, which modifications, how fast, how traceable" ranks for the method and pre-qualifies the demo.

    Risks and how to handle them

    • Overstating capabilities

      Only list features in the current release, dated.

    Builds on

    Evidence

    • Your websiteSitemap (7 URLs): the homepage, /brand, /blog and four posts ("YC Announcement", January 2026; "YC Launch" and "Extreme Velocity", February 2026; "Seed Announcement", April 2026). There are no product, peptide-mapping, use-case, docs, customer, careers or changelog pages in it, although the site links to /careers and /changelog.Source
    • Your websiteHomepage (rendered scan): H1 "The AI-native platform for next-generation protein characterization."; meta description "Peptide mapping, upgraded for protein therapeutics. 10x faster processing. Find what current tools miss. No file conversions, no friction."; logos for Y Combinator, Stanford, MIT, UC Berkeley, UCSF and UW Madison; no testimonials or case studies; demos booked through an embedded Cal.com scheduler; no free trial or published pricing. The headline changed from "Science" to the current message after December 2025.Source
    • Competitor researchGenedata Expressionist: "Mass Spec Analytics. One Enterprise Solution."; lists peptide mapping, intact mass and released glycans; an "end-to-end solution for multi-attribute method (MAM) implementations"; says it "fully supports GxP deployment and 21 CFR Part 11 requirements" with audit trails and version control.Source
    • Competitor researchProtein Metrics by Dotmatics: "Accelerate Biopharmaceutical Characterization & Quantification"; "vendor-neutral mass spectrometry software"; Byos desktop characterization, Byonic search engine and Byosphere cloud enterprise platform.Source
  • 09

    The homepage claims "10x faster processing" and "Find what current tools miss", but nothing public backs either claim. An analyst feature says buyers will need validation and accuracy proof, and that the platform needs published benchmarks against PEAKS and instrument-vendor software. NISTmAb (NIST Reference Material 8671) is a public antibody with known low-abundance modifications that labs already use for multi-lab peptide-mapping studies.

    High impactHigh effort First result in 2 months CTO

    First action

    Choose the public NISTmAb dataset and the comparison tools and settings.

    How to measure it

    Demos citing the benchmark

    Now
    –
    Target
    15 a quarter
    By
    2 quarters

    Steps

    1. 1

      Pick the data

      Public NISTmAb peptide-mapping raw files from more than one instrument.

      CTO 1 week

    2. 2

      Fix the protocol

      Tool versions, settings and scoring, written down before any runs.

      CEO 1 week

    3. 3

      Run and score

      Time, coverage, modifications found, false calls.

      Founding Engineer 2 weeks

    4. 4

      Independent check

      Ask an academic collaborator to rerun one tool.

      CEO 2 weeks

    5. 5

      Legal review

      Fair naming of other tools and their licences.

      COO 1 week

    6. 6

      Publish

      Preprint, web page and downloadable files.

      CTO 1 week

    7. 7

      Repeat

      Update with each major release.

      CTO each release

    First result
    2 months
    Cost
    Staff time plus any software licences for the comparison tools
    Owner
    CTO

    Smallest test

    Publish 10x Science's own NISTmAb results against the reference modification list.

    Why it works

    Run NISTmAb peptide-mapping data (public files, or a lab's own run) through 10x Science and the common alternatives, and publish run time, sequence coverage, modifications found and false calls, with the files, settings and versions so anyone can reproduce it. Release it as a preprint and a web page, and offer prospects a call to walk through it.

    Analytical scientists trust numbers they can rerun on a standard they know. A public benchmark turns the homepage's claims into evidence and gives every rep and partner the same proof.

    Risks and how to handle them

    • A competitor disputes the settings

      Publish every setting and invite them to submit their own optimal run.

    • Licence terms forbid publishing benchmarks

      Check each licence first; where forbidden, report only 10x Science against the NIST reference values.

    Evidence

    • Industry referenceNISTmAb (NIST Reference Material 8671) is a public IgG1κ monoclonal antibody reference with low-abundance modifications (methionine oxidation, deamidation, glycation), used in multi-laboratory peptide-mapping studies of workflow robustness and transferability.Source
    • News coverageAnalyst feature (Huge Magazine, March 2026): buyers will need validation, accuracy proof and compliance documentation; the platform needs published benchmarks against PEAKS and instrument-vendor software (Waters, Thermo Fisher and Bruker bundle their own); CROs such as Charles River and WuXi are possible distribution channels.Source
    • Your websiteHomepage (rendered scan): H1 "The AI-native platform for next-generation protein characterization."; meta description "Peptide mapping, upgraded for protein therapeutics. 10x faster processing. Find what current tools miss. No file conversions, no friction."; logos for Y Combinator, Stanford, MIT, UC Berkeley, UCSF and UW Madison; no testimonials or case studies; demos booked through an embedded Cal.com scheduler; no free trial or published pricing. The headline changed from "Science" to the current message after December 2025.Source
  • 10

    TechCrunch reports that 10x Science made its analyses traceable because regulatory compliance requires it, a real differentiator for AI in a regulated lab. Nothing on the site says so. Genedata's Expressionist page openly claims GxP deployment and 21 CFR Part 11 support with audit trails and version control, so that is the standard buyers will compare against.

    High impactMedium effort First result in 1 quarter COO

    First action

    List the traceability features in the current release and the gaps against Part 11 expectations.

    How to measure it

    Pilot-to-contract rate

    Now
    –
    Target
    +20%
    By
    2 quarters

    Steps

    1. 1

      Inventory features

      Audit trail, versioning, roles, e-records, evidence links.

      CTO 1 week

    2. 2

      Gap review

      Against customer validation questionnaires already received.

      COO 1 week

    3. 3

      Write the page

      Today, planned and not planned, in plain language.

      COO 1 week

    4. 4

      Expert review

      A quality or regulatory consultant checks the wording.

      COO 1 week

    5. 5

      Validation pack

      Requirements, test scripts and release notes template.

      CTO 3 weeks

    6. 6

      Publish and link

      From the product page and every pharma proposal.

      Founding Engineer 1 day

    First result
    1 quarter
    Cost
    Staff time plus a few days of consultant review
    Owner
    COO

    Smallest test

    Send the traceability summary to one open pharma deal and ask what is missing.

    Why it works

    Publish a page that states exactly what exists today and what is planned: how every identification links back to the spectra and the deterministic rule or model that made it, audit trails, versioning of models and settings, user roles, data handling and hosting, and the status of any GxP validation work. Offer a downloadable validation-support pack for customers who must validate the software themselves.

    "Can we use this for regulated work?" stops AI-native tools in pharma. An honest, specific answer moves the conversation from research use to process development and QC, where budgets are larger.

    Risks and how to handle them

    • Over-claiming compliance

      Say 'supports customer validation' unless validation is actually complete, and have the wording reviewed.

    Evidence

    • News coverageTechCrunch (April 22, 2026): founded December 2025; $4.8M seed led by Initialized Capital with Y Combinator, Civilization Ventures and Founder Factor; the founders worked in Nobel laureate Carolyn Bertozzi's Stanford lab; the platform pairs deterministic algorithms grounded in chemistry and biology with AI agents that interpret mass spectrometry data, and makes analyses traceable for regulatory compliance; it works with multiple major pharmaceutical companies and academic researchers; Rilas Technologies, which runs chemical analyses for clients, had used it for several weeks and said it speeds up its work; Initialized's Zoe Perret: "This is a SaaS platform that pharma has to pay for, every single month"; the money goes to more engineers, model refinement and new customers, and longer term to combining protein data with other cell data.Source
    • Competitor researchGenedata Expressionist: "Mass Spec Analytics. One Enterprise Solution."; lists peptide mapping, intact mass and released glycans; an "end-to-end solution for multi-attribute method (MAM) implementations"; says it "fully supports GxP deployment and 21 CFR Part 11 requirements" with audit trails and version control.Source
    • News coverageAnalyst feature (Huge Magazine, March 2026): buyers will need validation, accuracy proof and compliance documentation; the platform needs published benchmarks against PEAKS and instrument-vendor software (Waters, Thermo Fisher and Bruker bundle their own); CROs such as Charles River and WuXi are possible distribution channels.Source
  • 11

    The only path on the site is a Cal.com demo booking: no pricing, trial or explanation of how a pilot becomes a contract. The business is a monthly SaaS subscription, and pharma buyers have to plan procurement, security review and budget before they can start. The company already runs a public status page with 100% website uptime since August.

    Medium impactLow effort First result in 1 quarter COO

    First action

    Write down how the last three pilots turned into contracts, and the steps that took longest.

    How to measure it

    Median demo-to-pilot time

    Now
    –
    Target
    -30%
    By
    2 quarters

    Steps

    1. 1

      Map past deals

      Steps and delays in the last three pilots.

      COO 1 day

    2. 2

      Standardise the pilot

      Scope, duration and success criteria template.

      CEO 2 days

    3. 3

      Security pack

      Pre-filled answers to common questionnaires.

      CTO 1 week

    4. 4

      Write the page

      Three steps plus a pilot request form.

      COO 2 days

    5. 5

      Publish

      Prerendered and linked from the nav.

      Founding Engineer half a day

    6. 6

      Track

      Demo-to-pilot time per deal.

      COO monthly

    First result
    1 quarter
    Cost
    $0
    Owner
    COO

    Smallest test

    Send the three-step outline to the next new prospect after the demo.

    Build the monitor. A live page fed by the public registries and re-checked every day. Usually live within days.

    Book a working session

    Why it works

    Publish a short page with three steps: a scoped pilot (what data, how long, what success looks like), the security and quality review (links to the traceability page, the status page and a security questionnaire pack on request), and the subscription (how seats or usage are counted and what is included; 'from' pricing if the team is comfortable). Add a 'request a pilot' form alongside the demo booking.

    Champions inside pharma need something to forward to procurement. Explaining the path removes weeks of back-and-forth and signals that a small vendor is ready for enterprise.

    Risks and how to handle them

    • Showing prices anchors negotiations

      Describe the pricing model without numbers at first.

    Builds on

    Evidence

    • Your websiteHomepage (rendered scan): H1 "The AI-native platform for next-generation protein characterization."; meta description "Peptide mapping, upgraded for protein therapeutics. 10x faster processing. Find what current tools miss. No file conversions, no friction."; logos for Y Combinator, Stanford, MIT, UC Berkeley, UCSF and UW Madison; no testimonials or case studies; demos booked through an embedded Cal.com scheduler; no free trial or published pricing. The headline changed from "Science" to the current message after December 2025.Source
    • News coverageTechCrunch (April 22, 2026): founded December 2025; $4.8M seed led by Initialized Capital with Y Combinator, Civilization Ventures and Founder Factor; the founders worked in Nobel laureate Carolyn Bertozzi's Stanford lab; the platform pairs deterministic algorithms grounded in chemistry and biology with AI agents that interpret mass spectrometry data, and makes analyses traceable for regulatory compliance; it works with multiple major pharmaceutical companies and academic researchers; Rilas Technologies, which runs chemical analyses for clients, had used it for several weeks and said it speeds up its work; Initialized's Zoe Perret: "This is a SaaS platform that pharma has to pay for, every single month"; the money goes to more engineers, model refinement and new customers, and longer term to combining protein data with other cell data.Source
    • Your websiteStatus page (incident.io): tracks "Website" and "App"; "We're fully operational"; 100% website uptime August-November 2026, no incidents listed.Source
  • 12

    Pharma scientists usually cannot upload proprietary spectra to a new vendor until legal and IT approve, which can take months. PEAKS offers a Studio trial; 10x Science offers only a demo call. NISTmAb is public, well characterised and familiar to every analytical lab.

    High impactMedium effort First result in 2 months CTO

    First action

    Process one public NISTmAb dataset and freeze it as a demo workspace.

    How to measure it

    Workspace-to-pilot rate

    Now
    –
    Target
    20%
    By
    2 quarters

    Steps

    1. 1

      Prepare data

      Two or three public NISTmAb runs from different instruments.

      CTO 1 week

    2. 2

      Build the workspace

      Read-only tenant with rerun limits.

      Founding Engineer 2 weeks

    3. 3

      Guided tour

      Three clicks to the most interesting modification.

      CEO 3 days

    4. 4

      Gate and route

      Work-email request; alert the founders on sign-up.

      Founding Engineer 2 days

    5. 5

      Follow up

      Day-2 email offering a pilot on their own data.

      CEO ongoing

    6. 6

      Measure

      Activation events and pilot conversion.

      COO monthly

    First result
    2 months
    Cost
    Engineering time and hosting
    Owner
    CTO

    Smallest test

    Screen-share the frozen NISTmAb workspace in the next five demos and ask who wants access.

    Why it works

    Give each prospect a read-only workspace preloaded with NISTmAb peptide-mapping runs already processed: they can browse the modifications found, open the spectra behind each call and see the traceable evidence, then rerun with their own settings. Gate it with a work-email request and follow up with an offer to process their own data.

    Scientists believe what they can click through. A demo on familiar public data separates trying the product from the data-sharing approval, so evaluation starts weeks earlier.

    Risks and how to handle them

    • Competitors use the workspace

      Approve requests manually from work domains.

    Evidence

    • Industry referenceNISTmAb (NIST Reference Material 8671) is a public IgG1κ monoclonal antibody reference with low-abundance modifications (methionine oxidation, deamidation, glycation), used in multi-laboratory peptide-mapping studies of workflow robustness and transferability.Source
    • Competitor researchPEAKS (Bioinformatics Solutions): "Proteomics Software and CRO Solutions for Discovery and Validation"; vendor-neutral, AI-driven, "one-button" interface; PEAKS Studio, PEAKS Online and PEAKS AB for antibody de novo sequencing; a PEAKS Studio trial; pricing by request; it also runs its own lab services for antibody sequencing and modification profiling.Source
    • Your websiteHomepage (rendered scan): H1 "The AI-native platform for next-generation protein characterization."; meta description "Peptide mapping, upgraded for protein therapeutics. 10x faster processing. Find what current tools miss. No file conversions, no friction."; logos for Y Combinator, Stanford, MIT, UC Berkeley, UCSF and UW Madison; no testimonials or case studies; demos booked through an embedded Cal.com scheduler; no free trial or published pricing. The headline changed from "Science" to the current message after December 2025.Source
  • 13

    10x Science already works with multiple top-10 pharma companies and is paid monthly as SaaS, but a new account still has to agree a custom evaluation. Analysis that takes legacy tools weeks returns in minutes here, so a short, fixed pilot can show value faster than any rival can run a comparison.

    High impactLow effort First result in 1 month CEO

    First action

    Write the one-page pilot scope and the readout template.

    How to measure it

    Pilots converting to subscriptions

    Now
    –
    Target
    50%
    By
    2 quarters

    Steps

    1. 1

      Define scope

      Molecule, run count, turnaround, deliverables.

      CEO 1 day

    2. 2

      Set the price

      Below typical purchase-order thresholds, credited to year one.

      COO 1 day

    3. 3

      Data agreement

      A short standard data-handling addendum.

      COO 1 week

    4. 4

      Readout template

      Side-by-side, time saved, findings, next steps.

      CTO 2 days

    5. 5

      Offer it

      In every demo and on the how-to-buy page.

      CEO ongoing

    6. 6

      Review

      Conversion and objections after every five pilots.

      COO monthly

    First result
    1 month
    Cost
    Staff time; the pilot fee covers delivery
    Owner
    CEO

    Smallest test

    Offer the fixed pilot to the next three prospects.

    Why it works

    Package a standard pilot: one molecule, up to a set number of peptide-mapping runs from the customer's instruments, results with full evidence within a fixed number of working days, a side-by-side against their current method, and a readout meeting. Price it so it can go on a corporate card or a small purchase order, and credit it against the first subscription.

    A small fixed fee clears procurement faster than a contract, filters for serious buyers, and the side-by-side readout becomes the internal business case for the subscription.

    Risks and how to handle them

    • Pilots consume the small team

      Cap concurrent pilots and automate the readout.

    Evidence

    • HiringFounding Engineer (Y Combinator job board, open now): San Francisco or Menlo Park, $150K-$240K plus 0.50%-2.00% equity, 3+ years' experience; the post says the company is working with multiple top-10 pharma companies and has three scientist-founders from Stanford, MIT and UC Berkeley. The company's own careers page lists only "Customer Success Manager", marked "Coming Soon".Source
    • News coverageSeed coverage (Pulse 2.0): the round was oversubscribed; the models analyse "hundreds of thousands of spectra" and deliver "explainable insights in minutes"; a "deep memory" capability learns from each dataset over time, unlike tools that reset with each analysis; funds also go to partnerships across life sciences and to models for a wider range of molecular analysis; applications named include cancer, neurodegenerative and infectious disease research; Carolyn Bertozzi: "The field has outgrown its infrastructure."Source
    • News coverageTechCrunch (April 22, 2026): founded December 2025; $4.8M seed led by Initialized Capital with Y Combinator, Civilization Ventures and Founder Factor; the founders worked in Nobel laureate Carolyn Bertozzi's Stanford lab; the platform pairs deterministic algorithms grounded in chemistry and biology with AI agents that interpret mass spectrometry data, and makes analyses traceable for regulatory compliance; it works with multiple major pharmaceutical companies and academic researchers; Rilas Technologies, which runs chemical analyses for clients, had used it for several weeks and said it speeds up its work; Initialized's Zoe Perret: "This is a SaaS platform that pharma has to pay for, every single month"; the money goes to more engineers, model refinement and new customers, and longer term to combining protein data with other cell data.Source
  • 14

    An analytical services lab is already a public user, and an analyst feature names CROs as a likely distribution channel. PEAKS, the best-known vendor-neutral alternative, also sells its own lab services for antibody sequencing and modification profiling, so CROs that use it are buying from a competitor. 10x Science is software-only.

    High impactMedium effort First result in 1 quarter COO

    First action

    Ask the existing service-lab user what a partner program would need to include.

    How to measure it

    Partners processing monthly

    Now
    –
    Target
    5
    By
    2 quarters

    Steps

    1. 1

      Interview the first lab

      Pricing, reporting and support needs.

      COO 1 week

    2. 2

      Design the tiers

      Volume pricing and co-branded reports.

      COO 1 week

    3. 3

      Build report branding

      Partner logo and sign-off on exported reports.

      Founding Engineer 2 weeks

    4. 4

      Partner page

      Directory of certified partners for pharma.

      Founding Engineer 3 days

    5. 5

      Recruit

      Ten analytical service labs, led by the first partner's story.

      CEO 1 quarter

    6. 6

      Review

      Volume and client overlap quarterly.

      COO quarterly

    First result
    1 quarter
    Cost
    Discounts plus staff time
    Owner
    COO

    Smallest test

    Sign the existing lab as partner number one.

    Why it works

    Offer CROs and analytical service labs a partner tier: volume pricing, white-label or co-branded reports, priority support and a listing on a 'certified analysis partners' page that pharma prospects can use when they lack in-house capacity. Partners get faster turnaround to sell; 10x Science gets every partner client's data on its platform.

    Each CRO serves dozens of drug developers, so one partner brings many end users, and the 'we never compete with you' promise is a reason to switch that rivals with service arms cannot match.

    Risks and how to handle them

    • Partners undercut direct pharma deals

      Position partners for outsourced work, direct for in-house teams.

    Builds on

    Evidence

    • Competitor researchPEAKS (Bioinformatics Solutions): "Proteomics Software and CRO Solutions for Discovery and Validation"; vendor-neutral, AI-driven, "one-button" interface; PEAKS Studio, PEAKS Online and PEAKS AB for antibody de novo sequencing; a PEAKS Studio trial; pricing by request; it also runs its own lab services for antibody sequencing and modification profiling.Source
    • News coverageAnalyst feature (Huge Magazine, March 2026): buyers will need validation, accuracy proof and compliance documentation; the platform needs published benchmarks against PEAKS and instrument-vendor software (Waters, Thermo Fisher and Bruker bundle their own); CROs such as Charles River and WuXi are possible distribution channels.Source
    • News coverageTechCrunch (April 22, 2026): founded December 2025; $4.8M seed led by Initialized Capital with Y Combinator, Civilization Ventures and Founder Factor; the founders worked in Nobel laureate Carolyn Bertozzi's Stanford lab; the platform pairs deterministic algorithms grounded in chemistry and biology with AI agents that interpret mass spectrometry data, and makes analyses traceable for regulatory compliance; it works with multiple major pharmaceutical companies and academic researchers; Rilas Technologies, which runs chemical analyses for clients, had used it for several weeks and said it speeds up its work; Initialized's Zoe Perret: "This is a SaaS platform that pharma has to pay for, every single month"; the money goes to more engineers, model refinement and new customers, and longer term to combining protein data with other cell data.Source
  • 15

    "Find what current tools miss" is the homepage's sharpest claim and the reason a lab would change tools, but there is no public example of a miss. The platform produces explainable, evidence-linked calls, which is exactly the material for a visual example.

    Medium impactMedium effort First result in 1 month CTO

    First action

    Pick three modifications from public data that a standard search scores poorly.

    How to measure it

    Shares and demo mentions per entry

    Now
    –
    Target
    1 demo per 2 entries
    By
    2 quarters

    Steps

    1. 1

      Source examples

      Public datasets or customer-approved anonymised runs.

      CTO 1 week

    2. 2

      Write the template

      Modification, evidence, why missed, how found.

      CEO 1 day

    3. 3

      Produce visuals

      Annotated spectra exported from the platform.

      Founding Engineer weekly

    4. 4

      Publish

      Prerendered gallery page plus LinkedIn carousel.

      CTO weekly

    5. 5

      Peer check

      An outside mass spec scientist reviews each claim.

      CEO weekly

    6. 6

      Use in sales

      Send the relevant entry to prospects with similar molecules.

      CEO ongoing

    First result
    1 month
    Cost
    A few hours a week
    Owner
    CTO

    Smallest test

    Post one example on LinkedIn and track replies from scientists.

    Why it works

    Publish a weekly entry on public or approved data: the modification (for example a low-abundance deamidation or an unexpected glycoform on NISTmAb or a public dataset), the spectrum and fragment evidence, why a database search misses it, and how 10x Science reached the call. Collect them on one indexable page and post each on LinkedIn as a carousel.

    Analytical scientists love a good spectrum puzzle. Concrete examples prove the claim, spread in the community and give sales a library of 'have you checked for this?' openers.

    Risks and how to handle them

    • An example turns out to be wrong

      Peer review before posting and correct openly.

    Evidence

    • Your websiteHomepage (rendered scan): H1 "The AI-native platform for next-generation protein characterization."; meta description "Peptide mapping, upgraded for protein therapeutics. 10x faster processing. Find what current tools miss. No file conversions, no friction."; logos for Y Combinator, Stanford, MIT, UC Berkeley, UCSF and UW Madison; no testimonials or case studies; demos booked through an embedded Cal.com scheduler; no free trial or published pricing. The headline changed from "Science" to the current message after December 2025.Source
    • News coverageSeed coverage (Pulse 2.0): the round was oversubscribed; the models analyse "hundreds of thousands of spectra" and deliver "explainable insights in minutes"; a "deep memory" capability learns from each dataset over time, unlike tools that reset with each analysis; funds also go to partnerships across life sciences and to models for a wider range of molecular analysis; applications named include cancer, neurodegenerative and infectious disease research; Carolyn Bertozzi: "The field has outgrown its infrastructure."Source
    • Industry referenceNISTmAb (NIST Reference Material 8671) is a public IgG1κ monoclonal antibody reference with low-abundance modifications (methionine oxidation, deamidation, glycation), used in multi-laboratory peptide-mapping studies of workflow robustness and transferability.Source
  • 16

    The homepage shows Stanford, MIT, UC Berkeley, UCSF and UW Madison, and TechCrunch says academic researchers use the platform alongside pharma. In analytical science, tools spread through methods sections and the postdocs who later join industry, yet there is no academic offer or 'how to cite' on the site.

    Medium impactMedium effort First result in 6 months CEO

    First action

    List the academic users and ask which have papers in preparation.

    How to measure it

    Citing papers and preprints

    Now
    –
    Target
    5
    By
    12 months

    Steps

    1. 1

      Define the tier

      Eligibility, limits and terms.

      COO 1 week

    2. 2

      Citation page

      How to cite, with a DOI-backed reference.

      CTO 2 days

    3. 3

      Contact users

      Each academic group: papers planned, citation request.

      CEO 2 weeks

    4. 4

      Publications page

      List each paper as it appears.

      Founding Engineer ongoing

    5. 5

      Seminars

      Offer talks at university proteomics cores.

      CEO 1 quarter

    6. 6

      Alumni tracking

      Note when academic users move to industry.

      COO quarterly

    First result
    6 months
    Cost
    Compute for academic usage
    Owner
    CEO

    Smallest test

    Publish the 'how to cite' page and email current academic users.

    Why it works

    Launch an academic tier (free or nominal for non-commercial work, with a fair-use limit), a 'how to cite 10x Science' page with a citable reference (the benchmark preprint once it exists), and a page listing publications that used it. Ask each academic user to cite it and to present it at their department's mass spec meeting.

    Every methods-section citation is permanent, indexed proof, and today's academic users become tomorrow's analytical development leads at pharma companies.

    Risks and how to handle them

    • Commercial users claim academic terms

      Verify institutional email and non-commercial use.

    Evidence

    • Your websiteHomepage (rendered scan): H1 "The AI-native platform for next-generation protein characterization."; meta description "Peptide mapping, upgraded for protein therapeutics. 10x faster processing. Find what current tools miss. No file conversions, no friction."; logos for Y Combinator, Stanford, MIT, UC Berkeley, UCSF and UW Madison; no testimonials or case studies; demos booked through an embedded Cal.com scheduler; no free trial or published pricing. The headline changed from "Science" to the current message after December 2025.Source
    • News coverageTechCrunch (April 22, 2026): founded December 2025; $4.8M seed led by Initialized Capital with Y Combinator, Civilization Ventures and Founder Factor; the founders worked in Nobel laureate Carolyn Bertozzi's Stanford lab; the platform pairs deterministic algorithms grounded in chemistry and biology with AI agents that interpret mass spectrometry data, and makes analyses traceable for regulatory compliance; it works with multiple major pharmaceutical companies and academic researchers; Rilas Technologies, which runs chemical analyses for clients, had used it for several weeks and said it speeds up its work; Initialized's Zoe Perret: "This is a SaaS platform that pharma has to pay for, every single month"; the money goes to more engineers, model refinement and new customers, and longer term to combining protein data with other cell data.Source
  • 17

    The careers page signals a Customer Success Manager is coming, and the company is moving from early pharma accounts to new customers on a monthly subscription. Monthly SaaS lives or dies on whether scientists trust the output in the first weeks, and in a five-person team that knowledge sits with the founders.

    High impactMedium effort First result in 1 quarter COO

    First action

    Measure days from contract to first signed-off report for current accounts.

    How to measure it

    Median time to first trusted report

    Now
    –
    Target
    Under 14 days
    By
    2 quarters

    Steps

    1. 1

      Baseline

      Days to first signed-off report, per account.

      COO 2 days

    2. 2

      Define the milestone

      What 'trusted' means for each customer type.

      CEO 1 day

    3. 3

      Write the playbook

      Data transfer, formats, reference run, review, training.

      COO 1 week

    4. 4

      Instrument it

      Activation events in the app.

      Founding Engineer 1 week

    5. 5

      Health review

      Weekly list of accounts behind schedule.

      COO weekly

    6. 6

      Hand over

      Playbook and dashboard for the CSM.

      Customer Success Manager on hire

    First result
    1 quarter
    Cost
    Staff time only
    Owner
    COO

    Smallest test

    Track the milestone for the next two new accounts.

    Why it works

    Define one activation milestone (the customer's first report on their own data that their scientist signs off as matching or beating the current method) and write the steps to reach it: data transfer, instrument formats, a reference run, a side-by-side review and training. Track days to that milestone for every account, and hand the playbook to the CSM on day one.

    A clear first-value milestone predicts renewal, and writing it down now means the new hire scales the founders' onboarding instead of reinventing it.

    Risks and how to handle them

    • Every pharma account differs

      Keep one milestone and vary only the steps.

    Evidence

    • HiringFounding Engineer (Y Combinator job board, open now): San Francisco or Menlo Park, $150K-$240K plus 0.50%-2.00% equity, 3+ years' experience; the post says the company is working with multiple top-10 pharma companies and has three scientist-founders from Stanford, MIT and UC Berkeley. The company's own careers page lists only "Customer Success Manager", marked "Coming Soon".Source
    • News coverageTechCrunch (April 22, 2026): founded December 2025; $4.8M seed led by Initialized Capital with Y Combinator, Civilization Ventures and Founder Factor; the founders worked in Nobel laureate Carolyn Bertozzi's Stanford lab; the platform pairs deterministic algorithms grounded in chemistry and biology with AI agents that interpret mass spectrometry data, and makes analyses traceable for regulatory compliance; it works with multiple major pharmaceutical companies and academic researchers; Rilas Technologies, which runs chemical analyses for clients, had used it for several weeks and said it speeds up its work; Initialized's Zoe Perret: "This is a SaaS platform that pharma has to pay for, every single month"; the money goes to more engineers, model refinement and new customers, and longer term to combining protein data with other cell data.Source
    • Y CombinatorYC directory: batch Winter 2026, team of 5, San Francisco, founded 2025, tagged SaaS, B2B, Biotech and AI. The launch post, "10x Science: Unlocking the future of drug development", argues the bottleneck is characterization, not candidate design, and says the team is onboarding customers.Source
  • 18

    The press story is a sharp thesis: AI is generating more drug candidates than ever, and characterization, not design, is now the bottleneck. Carolyn Bertozzi put it as "The field has outgrown its infrastructure." The founders come from her lab, but the thesis lives only in other people's articles, not in anything 10x Science owns.

    Medium impactMedium effort First result in 2 months CEO

    First action

    Pick the first topic and invite one guest scientist.

    How to measure it

    Qualified registrants per session

    Now
    –
    Target
    60
    By
    2 quarters

    Steps

    1. 1

      Pick topics

      Six sessions from demo questions and gallery entries.

      CEO 1 day

    2. 2

      Book guests

      Academic users and partner labs.

      CEO 2 weeks

    3. 3

      Promote

      LinkedIn, founders' networks and partner newsletters.

      COO 2 weeks per session

    4. 4

      Run it

      Live walk-through on public data plus Q&A.

      CTO monthly

    5. 5

      Repurpose

      Transcript article and three clips.

      COO 1 week per session

    6. 6

      Follow up

      Offer the demo workspace to every attendee.

      CEO monthly

    First result
    2 months
    Cost
    Webinar tool and staff time
    Owner
    CEO

    Smallest test

    Run one session for current users and their colleagues.

    Why it works

    Run a monthly 45-minute technical session for analytical and process development scientists: one problem (a hard modification class, a regulatory expectation, a throughput crunch), a live walk-through on public data, and open Q&A. Record each one, publish the transcript as a prerendered article, and cut short clips for LinkedIn. Invite guest scientists from academic users and partner labs.

    Scientists attend for the method, not the pitch; registrants are self-identified prospects, and transcripts give the site the depth it lacks.

    Risks and how to handle them

    • Low attendance at first

      Co-host with a partner lab or university core to borrow its audience.

    Evidence

    • News coverageTechCrunch (April 22, 2026): founded December 2025; $4.8M seed led by Initialized Capital with Y Combinator, Civilization Ventures and Founder Factor; the founders worked in Nobel laureate Carolyn Bertozzi's Stanford lab; the platform pairs deterministic algorithms grounded in chemistry and biology with AI agents that interpret mass spectrometry data, and makes analyses traceable for regulatory compliance; it works with multiple major pharmaceutical companies and academic researchers; Rilas Technologies, which runs chemical analyses for clients, had used it for several weeks and said it speeds up its work; Initialized's Zoe Perret: "This is a SaaS platform that pharma has to pay for, every single month"; the money goes to more engineers, model refinement and new customers, and longer term to combining protein data with other cell data.Source
    • News coverageSeed coverage (Pulse 2.0): the round was oversubscribed; the models analyse "hundreds of thousands of spectra" and deliver "explainable insights in minutes"; a "deep memory" capability learns from each dataset over time, unlike tools that reset with each analysis; funds also go to partnerships across life sciences and to models for a wider range of molecular analysis; applications named include cancer, neurodegenerative and infectious disease research; Carolyn Bertozzi: "The field has outgrown its infrastructure."Source
    • Y CombinatorYC directory: batch Winter 2026, team of 5, San Francisco, founded 2025, tagged SaaS, B2B, Biotech and AI. The launch post, "10x Science: Unlocking the future of drug development", argues the bottleneck is characterization, not candidate design, and says the team is onboarding customers.Source
  • 19

    Top-10 pharma accounts prove the product, but they buy slowly. Mid-size and emerging biologics developers face the same characterization bottleneck with smaller analytical teams, and many publish peptide-mapping data in papers and public repositories. The platform turns hundreds of thousands of spectra into explainable results in minutes.

    High impactMedium effort First result in 1 month CEO

    First action

    Find ten companies with public peptide-mapping datasets.

    How to measure it

    Reply-to-meeting rate

    Now
    –
    Target
    15% of emails
    By
    1 quarter

    Steps

    1. 1

      Build the list

      Companies with public characterization datasets.

      COO 1 week

    2. 2

      Reanalyse

      Process public files and capture three findings each.

      Founding Engineer weekly

    3. 3

      Write the summary

      One page, neutral tone, evidence attached.

      CTO weekly

    4. 4

      Send

      Founder email to the analytical lead.

      CEO weekly

    5. 5

      Offer the pilot

      Fixed-scope pilot on internal data.

      CEO ongoing

    6. 6

      Review

      Reply rates by finding type.

      COO monthly

    First result
    1 month
    Cost
    Staff time and compute
    Owner
    CEO

    Smallest test

    Send five reanalysis emails and count replies.

    Why it works

    Each week, pick a few companies that have published peptide-mapping or characterization data, run the public files through 10x Science, and email the analytical lead a one-page summary: coverage, modifications, anything notable, with the evidence. Offer the fixed-scope pilot on their internal data. Keep it to public data and never imply problems with their product.

    A specific result on the prospect's own published data is the most relevant cold opener possible, and it shows speed instead of claiming it.

    Risks and how to handle them

    • Findings read as criticism

      Frame as 'what the software surfaced', avoid quality judgments, and offer to keep it private.

    Builds on

    Evidence

    • HiringFounding Engineer (Y Combinator job board, open now): San Francisco or Menlo Park, $150K-$240K plus 0.50%-2.00% equity, 3+ years' experience; the post says the company is working with multiple top-10 pharma companies and has three scientist-founders from Stanford, MIT and UC Berkeley. The company's own careers page lists only "Customer Success Manager", marked "Coming Soon".Source
    • News coverageSeed coverage (Pulse 2.0): the round was oversubscribed; the models analyse "hundreds of thousands of spectra" and deliver "explainable insights in minutes"; a "deep memory" capability learns from each dataset over time, unlike tools that reset with each analysis; funds also go to partnerships across life sciences and to models for a wider range of molecular analysis; applications named include cancer, neurodegenerative and infectious disease research; Carolyn Bertozzi: "The field has outgrown its infrastructure."Source

Big bets 2

Larger plays that can change the trajectory.

  • 20

    Seed coverage describes a "deep memory" capability that learns from each dataset over time, unlike tools that reset with every analysis. That is the strongest retention mechanism a monthly SaaS can have, but it is described as a feature, not shown as a growing asset the customer owns and would lose by leaving.

    High impactHigh effort First result in 2 quarters CTO

    First action

    Define the three things a customer's knowledge base should answer that no current tool can.

    How to measure it

    Net revenue retention

    Now
    –
    Target
    130%
    By
    12 months

    Steps

    1. 1

      Customer interviews

      What history they search for today and can't find.

      CEO 3 weeks

    2. 2

      Design the model

      Molecules, runs, modifications, decisions, evidence.

      CTO 1 month

    3. 3

      Isolation and audit

      Per-tenant data separation and traceability.

      CTO 1 month

    4. 4

      Build search and trends

      Cross-batch and cross-programme views.

      Founding Engineer 2 months

    5. 5

      Monthly learning report

      What improved on the customer's data.

      Founding Engineer 1 month

    6. 6

      Pilot with two accounts

      Measure usage and renewal intent.

      Customer Success Manager 1 quarter

    7. 7

      Price it

      Decide whether it is core or a premium tier.

      COO 1 month

    First result
    2 quarters
    Cost
    Two engineers for about two quarters
    Owner
    CTO

    Smallest test

    Send one customer a manual 'what we learned on your data' report and gauge the reaction.

    Why it works

    Productise it as a private, per-customer molecular knowledge base: every molecule, run, modification and decision, searchable and linked to the evidence, with trend views across batches and programmes. Show customers a monthly summary of what the system has learned on their data (new modification patterns, faster runs, fewer manual reviews), and keep strict data isolation.

    When the tool gets measurably better on a customer's own molecules each month, switching back to a stateless tool means losing institutional memory, which is the opposite of what pharma wants.

    Risks and how to handle them

    • Customers fear their data training shared models

      Make per-tenant learning explicit and contractual.

    • Scope creep into a full LIMS

      Stay focused on characterization data and decisions.

    Builds on

    Evidence

    • News coverageSeed coverage (Pulse 2.0): the round was oversubscribed; the models analyse "hundreds of thousands of spectra" and deliver "explainable insights in minutes"; a "deep memory" capability learns from each dataset over time, unlike tools that reset with each analysis; funds also go to partnerships across life sciences and to models for a wider range of molecular analysis; applications named include cancer, neurodegenerative and infectious disease research; Carolyn Bertozzi: "The field has outgrown its infrastructure."Source
    • News coverageTechCrunch (April 22, 2026): founded December 2025; $4.8M seed led by Initialized Capital with Y Combinator, Civilization Ventures and Founder Factor; the founders worked in Nobel laureate Carolyn Bertozzi's Stanford lab; the platform pairs deterministic algorithms grounded in chemistry and biology with AI agents that interpret mass spectrometry data, and makes analyses traceable for regulatory compliance; it works with multiple major pharmaceutical companies and academic researchers; Rilas Technologies, which runs chemical analyses for clients, had used it for several weeks and said it speeds up its work; Initialized's Zoe Perret: "This is a SaaS platform that pharma has to pay for, every single month"; the money goes to more engineers, model refinement and new customers, and longer term to combining protein data with other cell data.Source
  • 21

    Peptide mapping is the wedge, and the seed money is meant partly for models covering a wider range of molecular analysis. The enterprise incumbent, Genedata Expressionist, sells one platform for peptide mapping, intact mass and released glycans plus end-to-end MAM; PEAKS adds intact deconvolution and glycoproteomics. Labs prefer one platform per molecule, so a single-assay tool caps account size.

    High impactHigh effort First result in 3 quarters CTO

    First action

    Ask each current account which assay they would move next and how many runs a month they do.

    How to measure it

    Multi-assay accounts

    Now
    –
    Target
    50% of accounts
    By
    18 months

    Steps

    1. 1

      Rank assays

      By customer volume and willingness to pay.

      CEO 3 weeks

    2. 2

      Scope the first

      Inputs, outputs and accuracy bar.

      CTO 1 month

    3. 3

      Build on the evidence model

      Same traceability and report format.

      Founding Engineer 1-2 quarters

    4. 4

      Benchmark

      Public reference standard, as with peptide mapping.

      CTO 1 month

    5. 5

      Design partners

      Two accounts test before launch.

      Customer Success Manager 1 quarter

    6. 6

      Plan MAM

      Requirements from process development and QC users.

      CEO 1 quarter

    First result
    3 quarters
    Cost
    Two to three engineers for several quarters
    Owner
    CTO

    Smallest test

    Prototype intact-mass results for one design partner's molecule.

    Why it works

    Pick the next assay by customer pull (most likely intact and subunit mass, then released glycans), reuse the traceable evidence model, and link results across assays per molecule. Later, offer multi-attribute monitoring that turns peptide-mapping findings into tracked quality attributes across batches, where process development and QC budgets sit.

    Each added assay raises revenue per account without a new buyer, and cross-assay links (a modification seen in the peptide map and confirmed by intact mass) are something point tools cannot show.

    Risks and how to handle them

    • Spreading a small team too thin

      One new assay at a time, only after peptide mapping retention is strong.

    Builds on

    Evidence

    • Competitor researchGenedata Expressionist: "Mass Spec Analytics. One Enterprise Solution."; lists peptide mapping, intact mass and released glycans; an "end-to-end solution for multi-attribute method (MAM) implementations"; says it "fully supports GxP deployment and 21 CFR Part 11 requirements" with audit trails and version control.Source
    • Competitor researchPEAKS (Bioinformatics Solutions): "Proteomics Software and CRO Solutions for Discovery and Validation"; vendor-neutral, AI-driven, "one-button" interface; PEAKS Studio, PEAKS Online and PEAKS AB for antibody de novo sequencing; a PEAKS Studio trial; pricing by request; it also runs its own lab services for antibody sequencing and modification profiling.Source
    • News coverageSeed coverage (Pulse 2.0): the round was oversubscribed; the models analyse "hundreds of thousands of spectra" and deliver "explainable insights in minutes"; a "deep memory" capability learns from each dataset over time, unlike tools that reset with each analysis; funds also go to partnerships across life sciences and to models for a wider range of molecular analysis; applications named include cancer, neurodegenerative and infectious disease research; Carolyn Bertozzi: "The field has outgrown its infrastructure."Source

Wildcards 1

Unexpected experiments, each with a cheap way to test it.

  • 22

    10x Science's own story is that AI now generates more candidate drugs than ever and the bottleneck has moved to characterization. The companies producing those candidates (generative protein and antibody design platforms) and their pharma partners need fast, traceable measurement of what was actually made, and each design-make-test cycle produces mass spec data.

    High impactMedium effort First result in 2 quarters CEO

    First action

    List generative design companies that run in-house mass spec and contact two.

    How to measure it

    Active design partners

    Now
    –
    Target
    2
    By
    2 quarters

    Steps

    1. 1

      Map the field

      Design companies with in-house wet labs and mass spec.

      COO 2 weeks

    2. 2

      Define the API output

      Structured, machine-readable characterization results.

      CTO 1 month

    3. 3

      Approach two

      Founder-to-founder intros through investors and YC.

      CEO 1 month

    4. 4

      Pilot

      One design cycle measured end to end.

      CTO 1 quarter

    5. 5

      Co-publish

      Joint case study on cycle time.

      CEO 1 month

    6. 6

      Commercial terms

      Volume pricing and referral to their pharma partners.

      COO 1 month

    First result
    2 quarters
    Cost
    API work plus partnership time
    Owner
    CEO

    Smallest test

    Process one design company's public characterization data and send them the result.

    Why it works

    Offer design platforms an API and a partnership: their make-and-test step sends mass spec data to 10x Science and gets back structured, evidence-linked characterization (sequence confirmed, modifications, liabilities) that feeds the next design round. Co-publish one case study showing faster cycles, and sell through them to their pharma partners.

    It attaches 10x Science to the fastest-growing source of new molecules and turns the press thesis into a product; every partner's pipeline becomes recurring volume.

    Risks and how to handle them

    • Partners build their own analysis

      Win on traceability and depth, which they would have to rebuild from scratch.

    Evidence

    • News coverageTechCrunch (April 22, 2026): founded December 2025; $4.8M seed led by Initialized Capital with Y Combinator, Civilization Ventures and Founder Factor; the founders worked in Nobel laureate Carolyn Bertozzi's Stanford lab; the platform pairs deterministic algorithms grounded in chemistry and biology with AI agents that interpret mass spectrometry data, and makes analyses traceable for regulatory compliance; it works with multiple major pharmaceutical companies and academic researchers; Rilas Technologies, which runs chemical analyses for clients, had used it for several weeks and said it speeds up its work; Initialized's Zoe Perret: "This is a SaaS platform that pharma has to pay for, every single month"; the money goes to more engineers, model refinement and new customers, and longer term to combining protein data with other cell data.Source
    • Y CombinatorYC directory: batch Winter 2026, team of 5, San Francisco, founded 2025, tagged SaaS, B2B, Biotech and AI. The launch post, "10x Science: Unlocking the future of drug development", argues the bottleneck is characterization, not candidate design, and says the team is onboarding customers.Source
    • News coverageSeed coverage (Pulse 2.0): the round was oversubscribed; the models analyse "hundreds of thousands of spectra" and deliver "explainable insights in minutes"; a "deep memory" capability learns from each dataset over time, unlike tools that reset with each analysis; funds also go to partnerships across life sciences and to models for a wider range of molecular analysis; applications named include cancer, neurodegenerative and infectious disease research; Carolyn Bertozzi: "The field has outgrown its infrastructure."Source

03

How Programmable can help

Where an idea in this playbook is something Programmable builds or runs, it's listed here with what we'd do. Everything else is yours to run.

Have it built

ProgrammableAgency

1 of the 22 ideas are things Programmable builds and runs for its customers: pages, outreach, prospect lists, booking flows and monitors. Pick one, or send the whole list.

Monitors1A live page fed by the public registries and re-checked every day.

A 30-minute session with the engineer who would build it, not a sales call. You leave with a plan whether or not you hire us.

Book a working session

Usually live within days.

Tools for the rest

ProgrammableInfo

Turn the research into a list you can act on

These ideas start with finding the right companies. Info finds them and the right person at each, researches every one and drafts the outreach, then asks before it sends.

  • Build this list in Info for idea #19 (opens programmable.info in a new tab)

New accounts: 100,000 free credits with code BETA100K

Find the companies (opens programmable.info in a new tab)
ProgrammableTalk

Fill the events in this plan

These ideas are events. Talk gets registrants for them and tells you who's coming and what their company does before the day.

Plan an event (opens programmable.talk in a new tab)
ProgrammableDigital

Show it, don't just describe it

These ideas need something to show: a demo, a video, an animation, graphics or a deck. Digital turns screenshots or the site into all of them, in the company's own brand.

Make a demo (opens programmable.digital in a new tab)
More example playbooks and reviews

More growth playbooks

Other companies we have researched, each read from what they are hiring for.

  • Mcpfy growth strategyA full-stack platform for MCP: an open-source SDK to build MCP servers and apps for ChatGPT, Claude and AI agents, plus a cloud to deploy…20 growth ideas
  • SimpleClosure growth strategyA tech-enabled service that runs a company's full shutdown (legal filings, state withdrawals, final taxes, payroll account closures…21 growth ideas
  • D.Luxury growth strategyA Los Angeles growth firm for luxury and premium DTC brands that uses its DIGITALRx customer-profit system to find the customers who drive…21 growth ideas
  • Ontra growth strategyAI-powered software plus a global network of lawyers that automates private-markets legal and compliance work: contract negotiation (NDAs…22 growth ideas
  • Structured AI growth strategyAI agents that run QA/QC on construction drawing sets and Revit models: code compliance, cross-discipline clashes, firm standards and…23 growth ideas
  • Hyperspell growth strategyA company brain for AI agents: Hyperspell connects a company's tools (Slack, Gmail, Google Drive, Notion, Linear, Jira, HubSpot…22 growth ideas
  • SimpliFed growth strategyVirtual lactation and baby feeding support from IBCLCs and other providers, from pregnancy through weaning, billed to health plans, with…22 growth ideas
  • Milkyway growth strategyA Shopify app for same-day local delivery and doorstep returns, with live tracking, photo proof of delivery, package protection and…20 growth ideas

See every playbook and website review

Independent research. Programmable wrote this playbook from public sources, as they stood on November 10, 2026, and cites them throughout. 10x Science did not commission, review or endorse it, and Programmable is not affiliated with 10x Science. Company and product names are trademarks of their owners, used only to identify them. The ideas are suggestions and opinion, not professional, legal or financial advice, and not statements about how 10x Science runs its business.

Something wrong, or do you represent 10x Science? Email [email protected] and we will correct it or take it down.

30/60/90 roadmap

What to focus on in each month, and the ideas that carry it.

  1. Days 1 to 307 ideas

    Make the site readable and shareable, publish a fact sheet, the first case study and the open role, fix layout shift and page weight, and make the changelog public.

  2. Days 31 to 6012 ideas

    Proof and buying path: peptide-mapping page, NISTmAb benchmark, traceability page, how-to-buy page, reference-data demo, fixed-scope pilot, the 'missed modifications' gallery, CRO partners, academic program, onboarding playbook, webinars and biotech outreach.

  3. Days 61 to 903 ideas

    Commit to the big bets: deep memory as a per-customer knowledge base, adjacent assays, and a partnership with generative design platforms.

The research behind the plan

3 research areas, each summarised in a few lines. Open any of them for the full detail.

Customers

What customers say

Customers value speed: analysis that took weeks back in minutes. The most cited problem: months of manual, error-prone characterization work.

  • No file conversions between instrument formats
  • Legacy tools that start from zero with every analysis
  • In their words: “peptide mapping”

Market

Competitive landscape

4 competitors compared: PEAKS (Bioinformatics Solutions), Protein Metrics by Dotmatics, Genedata Expressionist and Instrument-vendor software (Thermo Fisher, Waters, Bruker).

  • Gap to exploit: Published, reproducible accuracy benchmarks for AI-native characterization
  • PEAKS (Bioinformatics Solutions): Desktop-first; sells lab services that compete with CRO users
  • Protein Metrics by Dotmatics: Part of a large portfolio; traditional search-based approach

Hiring signals

10x Science is a five-person team hiring its first engineers: an open Founding Engineer role on YC's job board ($150K-$240K, 0.5-2% equity, San Francisco or Menlo Park) says it is working with multiple top-10 pharma…

  • Founding Engineer: Working with multiple top-10 pharma; engineering is the first use of the seed. Ideas 6, 13, 19.

From the team that wrote this playbook

All products
  • ProgrammableAgencyWorking AI systems in days, not quarters (opens programmable.agency in a new tab)
  • ProgrammableInfoAn agent that finds, researches and asks first (opens programmable.info in a new tab)
  • ProgrammableDigitalScreenshots in, an animated product demo out (opens programmable.digital in a new tab)
  • ProgrammableWatchKnow the day a supplier falls out of compliance (opens programmable.watch in a new tab)
  • ProgrammableTalkGet registrants for your events, and know who’s coming (opens programmable.talk in a new tab)
  • ProgrammablePageText what you need, your customer gets a page that works (opens programmable.page in a new tab)
  • ProgrammableCommunityForums with labelled AI members, never empty (opens programmable.community in a new tab)
ProgrammableMarketing
ExamplesLeaderboardsProductsTermsPrivacyCookiesDPALegalContact

© 2026 AI-Powered Growth Intelligence